वैज्ञानिकों ने पता लगाया है कि हल्के लक्ष्णों वाले कोविड का काफी अवधि तक असर रहता है और लोगों के ठीक होने पर भी इसका प्रभाव पड़ता है। अमेरिका के लॉस एंजिल्स के शोधकर्ताओं ने पता लगाया है कि जिन लोगों में हल्के लक्ष्णों वाला कोरोना था उनमें ऐसे एंटीबाडी पाए गए हैं जो शरीर को खुद ही नष्ट करने लगते हैं और ऐसे मरीजों की रिकवरी में भी अधिक समय लगता है और ये एंटीबाडी उनकी कोशिकाओं को ही नष्ट करने लगते हैं।
सेडार सिनाई मेडिकल सेंटर के शोधकर्ताओं के हवाले से येरूशलम पोस्ट ने बताया कि इन मरीजों के शरीर में खुद को नष्ट करने वाले एंटीबा़डीज बनने से इन्हें ठीक होने में देरी होती है। इस दल ने 177 मरीजों पर शोध किया था।
यह शोध जर्नल ऑफ ट्रांसलेशनल मेडिसिन में छपा है और इसमें कहा गया है कि जिन लोगों को पहले कोविड संक्रमण हुआ था उनके शरीर में जो एंटीबाडीज बने थे उन्होंने बाद में अपनी ही कोशिकाओं को ही निशाना बनाना शुरू कर दिया था और इसी वजह से उन्हें ठीक होने में इतना समय लगा था।
उन्होंने अपने आसपास की कोशिकाओं को नष्ट कर दिया था और इसकी वजह ये इन मरीजों को कोरोना से उबरने में इतना समय लगा ।
यह भी पढ़े► ओमिक्रोन कोरोना के डेल्टा वेरिएंट के मुकाबले इम्युनिटी को चकमा देने में अधिक सक्षम: शोध
India's Ayush industry is expanding globally and its market size has grown significantly during the last two years of the Covid pandemic as the domestic trends re-established the traditional system of medicine, nearer mainstream medicines. But can it, and especially, its major constituent ayurveda, capture a bigger share in the global wellness market?
Ayush, which combines ayurveda, yoga, unani, siddha - all indigenous to India and among the world's oldest healthcare systems - and homeopathy, touts a holistic approach to health,
Ayurveda, central to the Ayush, is among the world's oldest traditional medical practice, but is beyond it, stressing the requirement of healthy and natural lifestyle, and an organic interconnectedness among body, mind, and spirit.
The approach of Ayush systems which aims at immunity promoting interventions as an effective, safer, accessible, and affordable way is the reason for their increased use globally during the pandemic.
India's AYUSH has reported tremendous growth in the last few years because of growing global and domestic demand, enabled by research and development in the sector.
According to a report from Ayush Ministry, with a turnover of $18.1 billion, the market size of the Indian AYUSH industry, as a whole, has grown by 17 per cent during 2014-2020.
Among its different product segments, plant derivatives experienced 21 per cent growth in the same period, followed by nutraceuticals (20.5 per cent), pharmaceuticals (15.8 per cent), plant extracts 14.7 per cent and herbal plants (14.3 per cent) as per the report.
The Research and Information System for Developing Countries (RIS) report titled 'AYUSH Sector in India: Prospects and Challenges', says that in terms of the global share, India has grown faster in the AYUSH market as compared to the world and accounts for about 2.8 per cent of the market, which is likely to hold even though disruptions in production are not ruled out.
"According to the RIS report, the market size of AYUSH in India has registered a growth of 17 per cent between 2014 and 2020. Despite the global slowdown in economic activity in 2020, the market for AYUSH is estimated to reach $23.3 billion in 2022.
Research and research in the Ayush sector is also being promoted with more comprehensive results to be revealed soon," said the ministry's media advisor, Sanjay Dev.
The Indian Medicines Pharmaceutical Corporation Ltd (IMPCL), the public sector manufacturing unit of the Ayush Ministry, has recorded a turnover of Rs 164.33 crore (tentative) for financial year 2020-21. This is the highest in the company's history and an all-time high profit of approximately Rs 12 crore is reported for the year.
In 2019-20, the company's revenue was Rs 97 crore, as per the ministry.
Ayurveda sector in India has registered 17 per cent growth which is consistent with the growth trajectory of the global ayurveda Industry. As estimated by the International Market Analysis Research and Consulting Group, the ayurveda market is expected to grow by around 15 per cent during 2020-2025.
The study has estimated the global market size of the herbal sector which was estimated at $657.5 billion in 2020 and is likely to touch $746.9 billion by 2022.
According to the Data Bridge Market Research study, the global herbal medicinal market is expected to reach $426.43 billion by 2028, growing at a CAGR of 5.34 per cent during 2021-2028.
Available market research on herbal and ayurveda medicine sector says that ayurveda constitutes a small portion of the total herbal market, but its growth potential is much higher.
The global traditional and complementary medicine market has been valued at around $360 billion. However, only a minor share of that market gos to ayurveda, between $7.2 billion-$9.6 billion.
The rising interest in ayurveda showcases potential of Indian medicine systems to be a global leader with a proper strategic vision and operational efficiency in the sector. (By Avinash Prabhakar)
Read More► Central Council for Research in Ayurvedic Sciences Launches Office
Toronto- Even as the newly reported Omicron variant is poised to replace Delta as the dominant variant across the world, a study led by an Indian-origin researcher shows that many mutations in the variant allow it to bond with human cells far more efficiently than previous strains.
The Omicron variant was first identified in South Africa in late November, and has since spread rapidly to 106 countries. The variant is now the dominant strain in many countries including the US, the UK, Denmark among others.
Of all the variants of coronaviruses so far, Omicron is the most heavily mutated with more than 30 mutations on its spike protein, which the virus uses to enter human cells. The variant also harbours a high number of mutations in regions of the spike protein that antibodies recognise, potentially dampening their potency.
Researchers from the University of British Columbia, Canada, studied Omicron using cryo-electron microscopy - a technique that provides images of the virus at incredibly high resolution.
The results, published pre-print and not peer-reviewed yet, showed that "Omicron has far greater binding affinity than the original SARS-CoV-2 virus" due to new bonds created between the virus and human cell receptors, Dr Sriram Subramaniam, lead scientist, was quoted as saying to the Daily Mail.
In addition, the researchers tested Omicron against human and monoclonal antibodies, finding that the variant is more resistant to these immune system particles than other variants.
"The Omicron variant is unprecedented for having 37 spike protein mutations - that's three to five times more mutations than any other variant," Subramaniam, a biochemistry professor at the University, was quoted as saying in a statement.
According to Subramaniam, the increased mutations on the spike protein are important for two reasons: "Firstly, because the spike protein is how the virus attaches to and infects human cells. Secondly, because antibodies attach to the spike protein in order to neutralise the virus."
The team probed Omicron's mutations through microscopic imaging, and found that some of the mutations create additional bonds between the virus and ACE2 receptors - a human cell receptor located throughout the body, the report said.
These new mutations appear to "increase binding affinity", Subramaniam said, indicating that Omicron can attach more strongly to human cells.
The researchers compared Omicron's binding affinity to that of the Delta variant and the original strain of the coronavirus.
"Overall, the findings show that Omicron has far greater binding affinity than the original SARS-CoV-2 virus, with levels more comparable to what we see with the Delta variant," Subramaniam said.
Subramaniam's team also examined the Omicron spike protein's ability to evade both human antibodies and antibodies from monoclonal antibody treatments.
This analysis confirmed real-world data, showing that Omicron is more capable of evading antibodies than previous variants - meaning that treatments are less successful, the report said.
"Notably, Omicron was less evasive of the immunity created by vaccines, compared to immunity stemming from natural infection in unvaccinated Covid patients," Subramaniam said, adding "this suggests that vaccination remains our best defence against the Omicron variant."
Both the Omicron variant's increased binding affinity and its capacity to evade antibodies are "likely contributing factors to its increased transmissibility," Subramaniam said. (Agency)
Read More► Even Triple Vaccination Cannot Limit Omicron Spread: BioNTech CEO
Jerusalem- Israeli researchers have found that SARS-CoV-2, the virus that causes Covid-19, harms the human immune system, Ben-Gurion University (BGU) in southern Israel said on Monday.
In a genetic study published in the journal iScience, BGU researchers tried to find out what causes the "stormy" nature of Covid-19, which is also manifested in an extreme reaction of the immune system, Xinhua news agency reported.
For this purpose, they analyzed for a year, using computational biology, gene expression in patients from around the world.
The team examined whether mitochondria, cell organs that produce energy, are damaged during Covid-19 illness, resulting in dysfunction of the body.
Surprisingly, the researchers identified damage to the mitochondria of immune system cells, rather than to lung cells' mitochondria.
The mitochondrial damage in immune cells explains the "cytokine storm" phenomenon, which is a reaction of the immune system, appearing with symptoms such as fever, swelling and extreme fatigue, the researchers said.
"Based on the results, it is possible to use existing treatments to target mitochondria and thus improve patients' condition," they concluded.
Read More► A Runny Nose and Itchy Throat? It May Be Omicron, Says Study
यरुशलम। इजरायल के शोधकर्ताओं ने पाया है कि कोरोनावायरस का सबसे बड़ा कारण सार्स-सीओवी-2 मानव प्रतिरक्षा प्रणाली को नुकसान पहुंचाता है। इसकी जानकारी सोमवार को दक्षिणी इजरायल में बेन-गुरियन यूनिवर्सिटी (बीजीयू) ने दी। समाचार एजेंसी सिन्हुआ की रिपोर्ट के अनुसार, आईसाइंस जर्नल में प्रकाशित एक आनुवंशिक अध्ययन में, बीजीयू के शोधकर्ताओं ने यह पता लगाने की कोशिश की है कि कोरोनावायरस के रफ्तार से फैलने का कारण क्या है, जो प्रतिरक्षा प्रणाली के बावजूद भी फैल रहा है।
इसका पता लगाने के लिए उन्होंने दुनिया भर के संक्रमितों में कम्प्यूटेशनल जीव विज्ञान, जीन एक्सप्रेशन का उपयोग करते हुए एक साल के लिए विश्लेषण किया।
टीम ने जांच के दौरान देखा कि क्या माइटोकॉन्ड्रिया, ऊर्जा पैदा करने वाले कोशिका अंग, कोरोना के दौरान क्षतिग्रस्त हो जाते हैं, जिसके कारण शरीर सही ढंग से फंक्शन नहीं कर पाता है।
शोधकर्ताओं ने फेफड़ों की कोशिकाओं के माइटोकॉन्ड्रिया के बजाय प्रतिरक्षा प्रणाली की कोशिकाओं के माइटोकॉन्ड्रिया के नुकसान की पहचान की।
शोधकर्ताओं ने कहा कि प्रतिरक्षा कोशिकाओं में माइटोकॉन्ड्रियल क्षति 'साइटोकाइन स्टॉर्म' की व्याख्या करती है। यह प्रतिरक्षा प्रणाली की प्रतिक्रिया है, जो बुखार, सूजन और अत्यधिक थकान जैसे लक्षणों के साथ दिखाई देती है।
उन्होंने, "परिणामों के आधार पर, माइटोकॉन्ड्रिया को लक्षित करने के लिए मौजूदा उपचारों का उपयोग करना संभव है और इस प्रकार संक्रमितों की स्थिति में सुधार होता है।"
London - If you are having cold-like conditions such as sniffles, headaches, and tiredness. you are likely to be positive for Covid's Omicron variant, according to a UK study.
The Zoe Covid study app asked hundreds of thousands of people to log their symptoms and the investigators have been looking at ones linked to both the dominant Delta variant and the new highly transmissible variant Omicron.
The most common signs of the virus reported between December 3 and 10 were a runny nose, headache, fatigue, sneezing, and a sore throat, the Daily Mail reported.
The study suggests that the super mutant virus is more akin to a cold than Covid.
On the contrary, typical Covid symptoms include a continuous cough, high temperature or change/loss of their sense of taste and smell.
Epidemiologist Professor Tim Spector, lead scientist of the ZOE Symptom Tracking Study, has urged Britons to keep an eye out for these tell-tale signs of Omicron in the run up to Christmas, and before meeting friends and relatives, the report said.
"Hopefully people now recognise the cold-like symptoms which appear to be the predominant feature of Omicron," he said.
"Omicron symptoms are predominantly cold symptoms, runny nose, headache, sore throat and sneezing, so people should stay at home as it might well be Covid.
"Ahead of Christmas, if people want to get together and keep vulnerable family members safe, I'd recommend limiting social contact in the run up to Christmas and doing a few Lateral Flow Tests just before the big family gathering."
The warning comes alongside numerous reports that Omicron causes milder illness than past variants but scientists are still trying to untangle whether it is intrinsically weaker or if the population has higher levels of immunity, or even both.
In separate comments this week, Professor Spector said "classic" Covid symptoms like a fever, cough, or loss of smell, are now only present in the minority of cases.
He added that Omicron appears to be chipping away at the UK's vaccine protection from infection, but that jabs were still critical to protecting people.
"We are also seeing two to three times as many mild infections in people with boosters in Omicron areas as we do in Delta variant areas, but they are still very protective and a vital weapon," he said.
Data from the UK Health Security Agency (UKHSA) also shows that the number of Covid positive cases which are so mild they show no symptoms have also steadily increased since vaccines started being rolled out on mass earlier this year.
However, Chief Medical Officer Chris Whitty dismissed these early findings and called for "serious caution".
Read More► Covovax Receives WHO Approval for Emergency Use